<DOC>
	<DOCNO>NCT02038946</DOCNO>
	<brief_summary>The purpose study assess clinical benefit Nivolumab , measure independent radiologic review committee ( IRRC ) -assessed objective response rate ( ORR ) subject FL lymphoma fail therapy CD20 antibody alkylating agent .</brief_summary>
	<brief_title>Study Nivolumab Subjects With Relapsed Refractory Follicular Lymphoma ( FL ) ( CheckMate 140 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Grade 1 , 2 , 3a FL without pathologic evidence transformation Male female , age 18 , relapse refractory FL lymphoma &gt; =2 prior treatment line ; 2 prior treatment line must include least CD20 antibody and/or alkylating agent Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 01 Known central nervous system lymphoma History interstitial lung disease Subjects active , know suspected autoimmune disease Prior allogeneic stem cell transplant Prior autologous stem cell transplant â‰¤12 week prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>